Protein-protein interactions
Protein–protein interactions (PPIs) play a central role in many biological pathways and processes. While many proteins perform their functions independently, the vast majority interact with others for proper biological activity. Important protein-protein interactions are found with chaperone proteins, heat shock proteins, microtubules, transcription factors, immune checkpoint proteins and cytokines. There are currently more than 400,000 known PPIs, and these interactions make up the interactomics of the organism, known as the interacterome. Aberrant protein-protein interactions are associated with several human diseases, notably those associated with epigenetics, immunology and cancer, and are also are the basis of multiple aggregation-related diseases, such as Creutzfeldt–Jakob and Alzheimer's disease.
Biotin labelled peptides
| Cat No. | Product Name | Activity |
|---|---|---|
| PP-010 | H10, biotinylated | Biotinylated version of anterior gradient 2 (AGR2) binding peptide H10 |
Cell penetrating peptides
| Cat No. | Product Name | Activity |
|---|---|---|
| PP-160 | 736-745-TAT | Inhibits the interaction of TRPV1 and AKAP79 |
| PP-250 | A11 | ANXA1–EphA2 interaction blocker |
| PP-220 | F1 | Blocks the association of IKKbeta and NEMO |
| PP-180 | Myr-tat-CBD3 | Blocks the CaV2.2–CRMP2 interaction |
| AS-010 | NT1–20 | Blocks ASIC1a binding to RIPK1 |
| PP-090 | P110 | Drp1 enzyme inhibitor and blocker of Drp1/Fis1 interaction |
| PP-210 | p28 | Binds to p53 and inhibits cop1 binding |
| KS-200 | st-Ht31 | AKAP-PKA interaction inhibitor |
| PP-190 | T100-Mut | Enhances the association of TRPA1 and TRPV1 |
| PP-130 | TAT-AKAP79 (326-336) | The key region of AKAP79 for interaction with TRPV1 |
| PP-270 | TAT-ANK | Dll4-Notch1 inhibitor |
| PP-200 | Tat-beclin 1 | Autophagy inducing peptide |
| PP-140 | TAT-CBD3 | CRMP2 - CaV2.2 interaction inhibitor |
| PP-150 | TAT-CBD3A6K | Optimised variation of CBD3 |
| PP-230 | Tat-CIRP | MD2 - CIRP interaction blocker |
| PP-340 | Tat-D3S2 | DIRAS3 - beclin1 interaction inhibitor |
| PP-370 | TAT-HuR-HNS3 | HuR-PARP1 interaction blocker |
| PP-040 | Tat-βsyn-degron | α-Synuclein knockdown peptide |
| PP-260 | Tat-NTS peptide | Blocks the interaction of ANXA1 with importin β |
| PP-400 | TAT-QFNP12 | NDRG2 - PPM1A binding blocker |
Peptides
| Cat No. | Product Name | Activity |
|---|---|---|
| PP-120 | (D)-PPA 1 | PD-1/PD-L1 interaction inhibitor |
| PP-100 | Ac2-26 | Annexin/lipocortin 1 mimetic |
| PP-060 | Bak BH3 | Bak BH3 sequence that binds to Bcl-xL |
| PP-080 | Bid BH3 | Fragment of the BH3 domain of BID |
| PP-070 | Bim BH3 | BH3 only protein Bim fragment |
| PP-390 | BRC4wt | Blocks BRCA2–RAD51 interaction |
| PP-170 | Caveolin-1 scaffolding domain peptide | The binding domain of caveolin-1 |
| IM-010 | CXCL8 (54-72) | C-terminal CXCL8 peptide fragment corresponding to the core CXCL8 - glycosaminoglycan (GAG) binding region |
| IM-020 | CXCL8 (54-72) scrambled control | Scrambled version of CXCL8 (54-72) for use as a control |
| IM-015 | E70K | Inhibits CXCL8-induced neutrophil transendothelial migration |
| CK-020 | HBP08 | CXCL12/HMGB1 heterocomplex inhibitor |
| PP-290 | KP1 | Disrupts TGF-β/TβR2 interaction |
| PP-030 | KSL 128114 | Binds the PDZ1 domain of syntenin |
| AM-185 | N-peptide | Binds the periplasmic chaperone protein chaperone SurA |
| PP-240 | NFAT Inhibitor | Calcineurin-NFAT interaction inhibitor |
| PP-300 | NP-12 | PD-1 - PD-L1 interaction blocker |
| PP-380 | PD-L1Pep-2 | Binds to PD-L1 |
| PP-350 | PDHPS1 | YAP signaling pathway inhibitor |
| PP-050 | PUMA BH3 | BH3 domain fragment of PUMA |
| KS-120 | R18 | 4.3.3 proteins antagonist |
| PP-310 | Rb4 | Induces expression of HMGB1 and calreticulin |
| GH-220 | RG33 | Apolipoprotein A1 (ApoA-I) mimetic, improves glucose clearance and control |
| PP-330 | RS17 | CD47 - SIRPα signalling inhibitor |
| CV-050 | SBP1 | Binds to the SARS-CoV-2 receptor binding domain |
| PP-360 | SMRwt | Disrupts the Nef-mortalin interaction, anti-metastatic |
| IG-050 | Synstatin | Syndecan-1 mediated integrin activation inhibitor |
| PP-280 | TPP-1 | Blocks PD-1/PD-L1 interaction |
| PP-320 | VGN50 | Blocks MYC activation |
Further reading
De Las Rivas and Fontanillo (2010) Protein-protein interactions essentials: key concepts to building and analyzing interactome networks. PLoS Comput. Biol. 6(6) e1000807 PMID: 20589078
Scott et al (2016) Small molecules, big targets: drug discovery faces the protein–protein interaction challenge. Nat. Rev. Drug Discov. 15 533 PMID: 27050677
Titeca et al (2019) Discovering cellular protein‐protein interactions: Technological strategies and opportunities. Mass Spec. Rev. 38 79 PMID: 29957823
Contact Information
To place an order, or for customer services, order processing or technical support please contact us on:
UK, Europe and RoW
Tel: (+44) 01392 422205Fax: (+44) 01392 279510
info@iscabiochemicals.com
USA and Canada
Tel: 610-994-1134
Toll Free: 855-FOCUS21 (855-362-8721)
Fax: 610-465-9100
France
CliniSciences
Tel : +33 9 77 40 09 09
Fax : +33 9 77 40 10 11
Orders and customer support : info@clinisciences.com
Germany, Switzerland, Austria
BIOZOL Diagnostics
Tel: +49 (089) 3799 666-6
Fax: +49 (089) 3799 666-99
Orders, Technical and Customer support: info@biozol.de
Italy
Labospace
Tel: +39 02 35980841
Fax +39 02 359808004
Orders: info@labospace.com
Spain and Portugal
Abyntek Biopharma
Tel: +34 94 404 80 80
Fax: +34 94 404 80 81
Orders: info@abyntek.com
BIOHUB INTERNATIONAL
上海起发实验试剂有限公司
Tel: +86-15921799099
Tel: +86-021-50724187
Fax: +86-021-50724961
Orders: sale3@78bio.com
India
BTL Biotechno Labs Pvt Ltd
Tel: +91-8860924629
07291852429
Orders, Technical and Customer support: info@biotechnolabs.com
Japan
Namiki Shoji Co.
Tel：+81-050-5527-9850
Fax：+81-3-3352-2196
email: globalbusiness1@namiki-s.co.jp